GlobeImmune Inc(NASDAQ:GBIM)’s stock gained 7.80% to $7.46. The company on Nov. 12 announced its third quarter 2014 financial results and corporate highlights. The company reported a net loss of $6.4 million and $14.5 million in the three and nine months ended Sept. 30, 2014, respectively, compared to a net loss of $0.7 million and $1.2 million for the same periods in 2013, respectively. Total research and development (R&D) expenses for the three and nine months ended Sept. 30, 2014, were $1.8 million and $5.4 million, respectively, compared to $2.5 million and $8.5 million for the same periods in 2013, respectively.

Should Investors Buy GBIM After The Recent Development? Find Out Here

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)’s shares climbed 9.31% to $5.40. The company on Dec. 11 announced that NW Bio’s CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer’s 25th Annual Healthcare Conference in New York City. The presentation included updates about the DCVax-Direct Phase I trial, including emerging observations about the clinical results, two new case studies (in lung cancer and another type of sarcoma), and plans for the upcoming Phase II trials.  The presentation also included brief updates about the expanding DCVax-L Phase III trial for GBM brain cancer, the early approval programs for DCVax-L in Germany and the UK, and the reimbursement negotiations process in Germany.

Is NWBO Going To Rise or Fall After Today’s Price Action? Find Out Here

Aegerion Pharmaceuticals, Inc.(NASDAQ:AEGR)’s shares gained 9.25% to $22.08. The company on Dec. 8 announced that on December 1, 2014, Aegerion granted stock options to purchase an aggregate of 36,350 shares of common stock to 12 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $20.90, the closing price of Aegerion’s common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion’s Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.

Can Traders Buy AEGR After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.